Canadian Meds |
Policy | Legal
Terms | Meds Index
Evista is used by women during menopause or post-menopausal period to keep bone tissue. A mechanism of the action is conditioned by selective modulating of the estrogen receptors, i.e. the active components of the drug interact with receptors of the female hormone estrogen and regulate its quality, and if necessary it increases its level, or provides antiestrogenic effect.
It provides a stimulate action on the non-reproductive tissues and inhibitory action on the reproductive tissues. This drug normalizes a balance of calcium in the body and increases density of the bone tissue of the femoral bone and spine. The drug reduces the removal of calcium from the body mainly by means of the reduction of its loss through excretory system. It also reduces the level of cholesterol.
Nowadays Evista is one of the best remedies for the treatment and prevention of osteoporosis in women.
A therapy with Evista is indicated for women of any age. The course of the treatment with this drug is calculated on the long period of time. The dosage and way of usage is indicated by the attending doctor individually depending on how the disease takes its course and how it is necessary to maintain healthy by this drug.
Usually the initial dose of Evista is 60 mg per day one time. If necessary the dosage can be adjusted.
A compulsory adjustment dose is not needed in patients of the senior age.
During the treatment it is necessary to prescribe the drugs of calcium additionally.
The drug is indicated only for the use of by women in post-menopausal period. It is contraindicated to take the drug during pregnancy as well as severe loss of calcium because it may cause changes in the development of fetus.
Taking it in the period of lactation the drug may provide negative effect on the child’s development.
It is not recommended to take it by the patients with the expressed dysfunctions of liver and kidney.
The drug Evista is contraindicated in the following cases: of thrombosis, hepatic failure, renal failure, uterine bleeding of the unknown aetiology, breast cancer, endometrium cancer, and also in case of the increased sensitivity to raloxifene, active component of the drug.
If the uterine bleeding occurs during the treatment, it is necessary to terminate the use of this medical product and have a complete examination.
© 2003-2017 Rx Meds Canada . All Rights Reserved